CR20220139A - Inhibidor de diacilglicerol aciltransferasa 2 - Google Patents

Inhibidor de diacilglicerol aciltransferasa 2

Info

Publication number
CR20220139A
CR20220139A CR20220139A CR20220139A CR20220139A CR 20220139 A CR20220139 A CR 20220139A CR 20220139 A CR20220139 A CR 20220139A CR 20220139 A CR20220139 A CR 20220139A CR 20220139 A CR20220139 A CR 20220139A
Authority
CR
Costa Rica
Prior art keywords
sup
inhibitor
diacylglycerol acyltransferase
inhibitors
acyltransferase
Prior art date
Application number
CR20220139A
Other languages
English (en)
Inventor
David James Edmonds
Kentaro Futatsugi
Daniel Jonathan Smaltz
Jack Chang Hung Lee
Kevin James Filipski
Michelle Renee Garnsey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20220139A publication Critical patent/CR20220139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen compuestos de la Formula (I) <img src="data:image/png;base64,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 (***)
CR20220139A 2019-10-04 2020-09-30 Inhibidor de diacilglicerol aciltransferasa 2 CR20220139A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911094P 2019-10-04 2019-10-04
US202063074123P 2020-09-03 2020-09-03
PCT/IB2020/059145 WO2021064590A1 (en) 2019-10-04 2020-09-30 Diacylglycerol acyltransferase 2 inhibitor

Publications (1)

Publication Number Publication Date
CR20220139A true CR20220139A (es) 2022-05-06

Family

ID=72826929

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220139A CR20220139A (es) 2019-10-04 2020-09-30 Inhibidor de diacilglicerol aciltransferasa 2

Country Status (17)

Country Link
US (2) US11471458B2 (es)
EP (1) EP4038060B1 (es)
JP (1) JP7161081B2 (es)
KR (1) KR20220079906A (es)
CN (1) CN114787146A (es)
AU (1) AU2020358955B2 (es)
CA (1) CA3095028A1 (es)
CL (1) CL2022000835A1 (es)
CO (1) CO2022004286A2 (es)
CR (1) CR20220139A (es)
EC (1) ECSP22026478A (es)
ES (1) ES2966340T3 (es)
IL (1) IL291763A (es)
MX (1) MX2022004035A (es)
PE (1) PE20221444A1 (es)
TW (1) TWI771766B (es)
WO (1) WO2021064590A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123700A1 (es) 2020-10-08 2023-01-04 Merck Sharp & Dohme Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
CN115429810B (zh) * 2021-06-03 2024-03-08 苏州禾研生物技术有限公司 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途
US20240254114A1 (en) 2022-12-02 2024-08-01 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride 0-acyltransferase 2 inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
MA24852A1 (fr) 1998-05-04 1999-12-31 Pfizer Prod Inc Derives d'hygromycine a et leur procede de preparation
PL201048B1 (pl) 1998-07-06 2009-03-31 Bristol Myers Squibb Co Bifenylosulfonamid jako dualny antagonista receptorów angiotensyny i endoteliny oraz jego zastosowanie
AU2005247684B2 (en) 2004-05-12 2008-10-23 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
CA2648852C (en) 2006-04-20 2012-12-11 Pfizer Products Inc. Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2010013161A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
PE20120668A1 (es) 2009-03-11 2012-06-01 Pfizer Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
US8993556B2 (en) * 2009-04-21 2015-03-31 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as HSP90 inhibitors
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
EA020106B1 (ru) 2009-06-05 2014-08-29 Пфайзер Инк. Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr119
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
WO2013137628A1 (ko) 2012-03-16 2013-09-19 한국생명공학연구원 신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용
MA37385B1 (fr) * 2012-04-06 2019-09-30 Pfizer Inc Etat De Delaware Inhibiteurs de diacylglycérol-acyltransférase 2
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
AP2016009407A0 (en) * 2014-03-17 2016-08-31 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
EP3188732B1 (en) 2014-09-05 2019-07-24 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036636A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188731B1 (en) 2014-09-05 2019-04-03 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
PL3555064T3 (pl) 2016-12-16 2023-03-06 Pfizer Inc. Agoności receptora GLP-1 i ich zastosowania
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ

Also Published As

Publication number Publication date
EP4038060B1 (en) 2023-11-15
TWI771766B (zh) 2022-07-21
US11471458B2 (en) 2022-10-18
CL2022000835A1 (es) 2023-01-27
WO2021064590A1 (en) 2021-04-08
JP2022543499A (ja) 2022-10-12
EP4038060A1 (en) 2022-08-10
KR20220079906A (ko) 2022-06-14
IL291763A (en) 2022-06-01
US11065249B2 (en) 2021-07-20
CA3095028A1 (en) 2021-04-04
CO2022004286A2 (es) 2022-04-29
EP4038060C0 (en) 2023-11-15
ES2966340T3 (es) 2024-04-22
ECSP22026478A (es) 2022-05-31
PE20221444A1 (es) 2022-09-21
JP7161081B2 (ja) 2022-10-25
AU2020358955B2 (en) 2023-08-17
US20210100796A1 (en) 2021-04-08
US20210100798A1 (en) 2021-04-08
AU2020358955A1 (en) 2022-04-21
MX2022004035A (es) 2022-05-02
CN114787146A (zh) 2022-07-22
TW202126635A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
MX2022004035A (es) Inhibidor de diacilglicerol aciltransferasa 2.
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CR20220351A (es) Inhibidores de proteínas kras mutantes
CR20200416A (es) Nuevos compuestos heterocíclicos
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX2018006287A (es) Inhibidores de acc de triazol y usos de los mismos.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
AU2018274723A1 (en) Benzimidazolone derived inhibitors of BCL6
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2022006711A (es) Nuevos inhibidores de braf como rompedores de la paradoja.
MX2020012760A (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
MA42776B1 (fr) Composés utiles pour l&#39;inhibition du ror-gamma-t
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
MX2023011014A (es) Inhibidores de heteroarílo de la calicreína plasmática.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2020014276A (es) Compuestos policiclicos como inhibidores de epoxido hidrolasa soluble.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2023002691A (es) Desimetrización de diol mediante sustitución aromática nucleófila.
MX2022007255A (es) Derivado de amino arilo novedoso util como inhibidor de diaciglicerol aciltransferasa 2 y uso del mismo.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
WO2021076817A3 (en) Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2